Fenretinide, Visual Cycle Modulator, for Dry AMD: ReVision

NOT RECRUITING

Description: ReVision Therapeutics has completed a 246-participant Phase II clinical trial of fenretinide, a visual cycle modulator, for the treatment of dry age-related macular degeneration (AMD). The orally administered drug slowed the progress of dry AMD as well as the advancement of dry AMD to wet AMD. By slowing the visual cycle, the drug is intended to reduce the build-up of toxic by-products in the retina (retinal pigment epithelium) that cause vision loss in dry AMD and potentially other retinal conditions.

Trial Status: Completed; working toward Phase III clinical trial.

Articles:
Fenretinide Slows Dry AMD, Reduces Incidence of Wet AMD

Additional Information:
Fenretinide clinical trial listing on Clinical Trials.gov